In the race to find new oncology treatments, solid tumor clinical trials are continuing to pave the way in the discovery and approval of effective new anti-cancer therapies, including combination immunotherapies and other forms of innovative targeted approaches.
科学的イノベーションで業界をリードする
Our Immuno-Oncology Project Team focuses exclusively on studies of therapies that incite the immune system to combat cancer. 臨床チームは、固形腫瘍を対象とした精密医療のための新しい手法をサポートし、臨床開発の全相にわたり併用免疫療法や複合的治験デザイン（バスケット試験、プラットフォーム試験、アンブレラ試験など）を含む、最先端の治療法に取り組んでいます。
Our experience is diverse, involving a breadth of immuno-oncology therapies and mechanisms of action, including 83 studies with checkpoint inhibitors (CPIs) and 21 studies with genetically modified organisms (GMOs). 免疫療法の臨床試験のパイオニアとしてWe conducted the studies that led to the approval of the very first checkpoint inhibitor, seeing it all the way through from Phase 1 to marketing authorization and commercialization.
We have the necessary experience to operationalize your immuno-oncology studies across a wide range of disease settings and tumor types. Based on this deep expertise, we can support sites with our medical oncologists to ensure a robust evaluation of efficacy to obtain actionable data for registration studies. We are the only CRO to field dedicated Medical Site Liaisons (MSLs) for this purpose.
